Dorsey Wright & Associates Takes $2.24 Million Position in Abivax SA Sponsored ADR $ABVX

Dorsey Wright & Associates purchased a new stake in Abivax SA Sponsored ADR (NASDAQ:ABVX) during the fourth quarter, Holdings Channel reports. The institutional investor purchased 16,620 shares of the company’s stock, valued at approximately $2,241,000.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in ABVX. EverSource Wealth Advisors LLC raised its position in Abivax by 4,612.5% during the third quarter. EverSource Wealth Advisors LLC now owns 377 shares of the company’s stock worth $32,000 after acquiring an additional 369 shares during the period. Caitong International Asset Management Co. Ltd grew its position in shares of Abivax by 661.5% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 396 shares of the company’s stock valued at $53,000 after purchasing an additional 344 shares during the period. T. Rowe Price Investment Management Inc. acquired a new stake in shares of Abivax in the fourth quarter valued at about $61,000. WPG Advisers LLC grew its position in shares of Abivax by 125.9% in the fourth quarter. WPG Advisers LLC now owns 454 shares of the company’s stock valued at $61,000 after purchasing an additional 253 shares during the period. Finally, Union Bancaire Privee UBP SA purchased a new stake in shares of Abivax during the fourth quarter worth about $67,000. Hedge funds and other institutional investors own 47.91% of the company’s stock.

Analyst Ratings Changes

Several research analysts recently weighed in on the stock. Citigroup restated an “outperform” rating on shares of Abivax in a research report on Tuesday, June 2nd. BTIG Research reiterated a “buy” rating and set a $150.00 price objective on shares of Abivax in a research note on Tuesday. Barclays increased their target price on Abivax from $142.00 to $148.00 and gave the company an “overweight” rating in a report on Tuesday, March 24th. Wall Street Zen upgraded Abivax from a “sell” rating to a “hold” rating in a research report on Saturday, May 23rd. Finally, Citizens Jmp lifted their price target on Abivax from $131.00 to $187.00 and gave the stock a “market outperform” rating in a research note on Tuesday, June 2nd. Twelve analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $130.08.

Abivax Stock Down 1.0%

ABVX stock opened at $99.15 on Friday. The business has a fifty day moving average of $114.46 and a two-hundred day moving average of $118.30. The stock has a market cap of $7.91 billion, a price-to-earnings ratio of -19.03 and a beta of 0.69. Abivax SA Sponsored ADR has a 52-week low of $5.69 and a 52-week high of $148.83.

Abivax (NASDAQ:ABVX) last announced its quarterly earnings results on Friday, May 22nd. The company reported ($0.71) EPS for the quarter, beating the consensus estimate of ($0.94) by $0.23. The business had revenue of $1.56 million during the quarter, compared to analyst estimates of $0.40 million. As a group, sell-side analysts anticipate that Abivax SA Sponsored ADR will post -3.4 EPS for the current year.

Abivax Company Profile

Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.

Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.